Baseline PSA distribution and estimated prevalence of prostate cancer in men participated in PSA screening for the first time: Longitudinal changes for 25 years in Gunma and international comparison between Gunma and ERSPC, Rotterdam in 1990's

Baseline PSA distribution and estimated prevalence of prostate cancer in men participated in PSA screening for the first time: Longitudinal changes for 25 years in Gunma and international comparison between Gunma and ERSPC, Rotterdam in 1990's - International comparison of PSA distribution and estimated prevalence of prostate cancer in men participated in PSA screening.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029069

Enrollment

100000

Registered

2017-09-11

Start date

2017-09-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Participants in the Gunma section will be about 75,000 men aged 50 to 79 who underwent PSA screening for the first time in the population-based screening in Gunma Prefecture, Japan, between January 1992 and December 2016. Participants in the Rotterdam section will be about 20,000 men aged 50 to 79 who participated in the first round of PSA screening in the ERSPC, Rotterdam, between November 1993 and December 1999.

Exclusion criteria

Exclusion criteria: Men who have rejected to participate in the study.

Design outcomes

Primary

Measure	Time frame
1) Investigating changes in the baseline PSA distributions with age and estimated AIR during 25 years in Gunma section. 2) International comparison in the baseline PSA distributions with age and estimated AIR between Gunma and Rotterdam.	—

Secondary

Measure	Time frame
1) Investigating 25-year changes in the clinicopathological features of prostate cancer detected at the initial screening in Gunma section. 2) International comparison in the clinicopathological features of prostate cancer detected at initial screening in Gunma and Rotterdam sections.	—

Countries

Japan,Europe

Contacts

Public ContactKazumi Masui

Gunma University Hospital Clinical Investigation and Research Unit

hitotaisho-ciru@ml.gunma-u.ac.jp027-220-8740

Outcome results